Rentschler Focuses On Biotechnology And Sells Rentschler Pharma GmbH
Laupheim, Germany - Rentschler will invest another 14 million Euro in the expansion of Rentschler Biotechnologie GmbH at the Laupheim site. Only recently a 50 million Euro investment in biotechnological development and production facilities was completed.
The first sod will already be taken this year for the new construction of a logistics centre and the expansion of the administrative building in Erwin-Rentschler-Straße in Laupheim.
In the logistics centre a high-rise warehouse, several cold warehouses, an incoming goods department, a dispatch area and the company's transport fleet will be located. The move into the new buildings is planned for end of 2009.
With this step, Rentschler concentrates all of the biotech activities at one site and thus provides the frame for further growth.
Within the scope of this business concentration on the development and manufacture of biopharmaceutical drug products Dr. Rentschler Holding GmbH & Co. KG has sold as per today all of the shares of Rentschler Pharma GmbH to Riemser Arzneimittel AG in Greifswald/Isle of Riems, Eastern Germany.
Riemser is planning to further expand its business division contract manufacture from the Laupheim site. In this connection Rentschler Pharma GmbH will be renamed to Riemser Speciality Production GmbH.
Rentschler Biotechnologie GmbH is an internationally operating contract organisation with many years of experience in the development, production and registration of drug products based on biopharmaceutical drug substances. The range of services of Rentschler Biotechnologie GmbH also comprises the sterile filling of pre-filled syringes and injection vials. In Germany, the company employs more than 400 people.
The company Rentschler, founded in 1927, concentrates its activities on the business sector biotechnology. Rentschler Biotechnologie GmbH is a subsidiary of the medium-sized family-owned business Dr. Rentschler Holding GmbH & Co. KG headquartered Laupheim, Baden-Wurttemberg, Germany.
SOURCE: Rentschler Biopharma